Tests ALN-ANG3 in adults with diabetic kidney disease
Tests the experimental drug ALN-ANG3 against a placebo in adults with diabetic kidney disease.
Plain-language title generated from the registry record
Registry title: Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Key facts
- Where
- Ann Arbor, Arlington, Bethlehem, Binghamton, Chattanooga, Chicago, City of Saint Peters, Dallas, DeSoto, Doral, El Paso, Greenville, Hialeah, Hollywood, Houston, Huntington Beach, Huntsville, Kansas City, Katy, Las Vegas, Little Rock, Margate, McKinney, Miami, Miami Springs, Miramar, Monroe, New Bern, New Haven, Northridge, Omaha, Orlando, Oxnard, Pembroke Pines, Pontiac, Port Orange, Port Saint Lucie, Salinas, San Antonio, San Dimas, Santa Clarita, Savannah, Spokane, Tamarac, Tarzana, The Bronx, Valencia, Victorville, West Chester, West Palm Beach, and Winston-Salem, United StatesSee the 59 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07271186, who can take part
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- Arlington Nephrology, PLLC.Arlington, United StatesTaking people
- Northeast Clinical Research CenterBethlehem, United StatesTaking people
- Velocity Clinical ResearchBinghamton, United StatesTaking people
- Southeast Renal Research InstituteChattanooga, United StatesNo longer taking part
- Research by Design, LLC - Internal MedicineChicago, United StatesTaking people
- Elixia MNACity of Saint Peters, United StatesTaking people
- M3 Wake Research Dallas - Internal MedicineDallas, United StatesTaking people
- Revival Research Institute, LLCDallas, United StatesTaking people
- Epic Medical Research LLCDeSoto, United StatesTaking people
- D&H Doral Research CenterDoral, United StatesTaking people
- El Paso Kidney Specialists-Davita Clinical ResearchEl Paso, United StatesTaking people
- Eastern Nephrology Associates - Greenville WestGreenville, United StatesTaking people
- AGA Clinical TrialsHialeah, United StatesTaking people
- Convenient Medical CenterHialeah, United StatesTaking people
- Elixia HollywoodHollywood, United StatesTaking people
- Clinical Trial Network LLCHouston, United StatesTaking people
- Juno Research, LLCHouston, United StatesTaking people
- Prolato Research LLCHouston, United StatesTaking people
- AME Clinical ResearchHuntington Beach, United StatesTaking people
- Apogee Clinical Research, LLCHuntsville, United StatesTaking people
- Clinical Research Consultants, LLCKansas City, United StatesTaking people
- Gulf Coast Clinical ResearchKaty, United StatesTaking people
- R&H Clinical Research, Inc.Katy, United StatesTaking people
- DaVita Clinical ResearchLas Vegas, United StatesTaking people
- Applied Research Center of ArkansasLittle Rock, United StatesTaking people
- D&H Pompano Research CenterMargate, United StatesTaking people
- Sunbeam Clinical ResearchMcKinney, United StatesTaking people
- D&H National Research Centers, IncMiami, United StatesTaking people
- LCC Medical Research InstituteMiami, United StatesTaking people
- Regenerate Primary Medical Research, LLCMiami, United StatesTaking people
- Ocean Blue Medical Research Center - Internal MedicineMiami Springs, United StatesTaking people
- Innovia Research CenterMiramar, United StatesTaking people
- IMA Clinical ResearchMonroe, United StatesTaking people
- Eastern Nephrology Associates - New BernNew Bern, United StatesTaking people
- Yale UniversityNew Haven, United StatesTaking people
- Amicis Research CenterNorthridge, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- Central Florida Kidney Specialists OakwaterOrlando, United StatesTaking people
- FOMAT - Vista del Mar Medical GroupOxnard, United StatesTaking people
- Bolanos Clinical ResearchPembroke Pines, United StatesTaking people
- Elixia Michigan Kidney ConsultantsPontiac, United StatesTaking people
- Progressive Medical ResearchPort Orange, United StatesTaking people
- CDC Research InstitutePort Saint Lucie, United StatesTaking people
- Central Coast NephrologySalinas, United StatesNo longer taking part
- Clinical Advancement CenterSan Antonio, United StatesTaking people
- University of Texas Health - San AntonioSan Antonio, United StatesTaking people
- North America Research InstituteSan Dimas, United StatesTaking people
- Amicis Research CenterSanta Clarita, United StatesTaking people
- Privia Medical Group of Georgia, LLCSavannah, United StatesTaking people
- Providence Medical Research CenterSpokane, United StatesTaking people
- D&H Tamarac Research CenterTamarac, United StatesTaking people
- Valiance Clinical ResearchTarzana, United StatesTaking people
- CHEAR Center LLCThe Bronx, United StatesTaking people
- Amicis Research CenterValencia, United StatesTaking people
- National Institute of Clinical Research, IncVictorville, United StatesTaking people
- Suburban Research AssociatesWest Chester, United StatesTaking people
- Metabolic Research InstituteWest Palm Beach, United StatesTaking people
- Brookview Hills Research Associates, LLCWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals
- Trial code
- NCT07271186EU 2026-527519-41-00
- Record updated
- 27 October 2026
- Original description
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.Read full original descriptionShow less
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALN-ANG3 in Participants With Diabetic Kidney Disease
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.
The aim of the study is to see how safe and effective the study drugs are.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Inclusion: Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management; Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening; eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening; Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening.
Exclusion: Renal disease that required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or kidney transplantation; Known medical history or clinical evidence indicative of non-diabetic renal disease; Medically unstable as assessed by the investigator or hospitalization (ie, >24 hours) within 30 days of the screening visit; NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply.